Related Experiment Video

Updated: Aug 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial

F R Den Hartog1, P M Van Kalmthout, T T Van Loenhout

  • 1Department of Cardiology, Gelderse Vallei Hospital, Ede, The Netherlands.

International Journal of Clinical Practice
|July 17, 2001
PubMed

Insights

Early statin therapy initiation after acute coronary events is safe and well-tolerated. This pilot study found pravastatin safe for patients with acute myocardial infarction or unstable angina, showing no significant adverse events compared to placebo.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are proven to reduce coronary events and mortality.
  • Limited research exists on the benefits of early statin initiation during the acute phase of coronary syndromes.

Purpose of the Study:

  • To evaluate the safety and tolerability of early statin therapy initiation in patients experiencing acute coronary syndromes.

Main Methods:

  • A randomized, double-blind, placebo-controlled, three-month pilot study.
  • 100 patients with acute myocardial infarction or unstable angina and elevated LDL cholesterol (>3.5 mmol/l) were enrolled.
  • Participants received either pravastatin 40 mg daily or a placebo within 48 hours of hospital admission.

Main Results:

  • Pravastatin was found to be safe and well-tolerated in this patient cohort.
  • No statistically significant differences were observed in mortality, myocardial infarction (MI), or drug-related adverse events between the pravastatin and placebo groups.
  • Patient groups were well-matched at baseline.

Conclusions:

  • Early initiation of pravastatin therapy following an acute coronary event is safe and well-tolerated.
  • Larger, long-term studies are required to confirm these preliminary findings and assess potential cardioprotective benefits.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...